2024
Artificial intelligence applied to electrocardiographic images for the risk stratification of cancer therapeutics-related cardiac dysfunction
Oikonomou E, Sangha V, Dhingra L, Aminorroaya A, Coppi A, Krumholz H, Baldassarre L, Khera R. Artificial intelligence applied to electrocardiographic images for the risk stratification of cancer therapeutics-related cardiac dysfunction. European Heart Journal 2024, 45: ehae666.3190. DOI: 10.1093/eurheartj/ehae666.3190.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionImmune checkpoint inhibitorsGlobal longitudinal strainLeft ventricular systolic dysfunctionNon-Hodgkin's lymphomaCardiac dysfunctionAI-ECGNegative control analysesAssociated with higher incidenceVentricular systolic dysfunctionCohort of patientsRisk stratification strategiesCheckpoint inhibitorsTrastuzumab exposureSystolic dysfunctionRisk stratificationBreast cancerRisk biomarkersSecondary outcomesLongitudinal strainStratification strategiesTrastuzumabPatientsHigher incidenceAnthracyclinesArtificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images.
Oikonomou E, Sangha V, Dhingra L, Aminorroaya A, Coppi A, Krumholz H, Baldassarre L, Khera R. Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images. Circulation Cardiovascular Quality And Outcomes 2024 PMID: 39221857, DOI: 10.1161/circoutcomes.124.011504.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionGlobal longitudinal strainLeft ventricular systolic dysfunctionCardiac dysfunctionBreast cancerNon-Hodgkin lymphoma therapyNon-Hodgkin's lymphomaVentricular systolic dysfunctionAssociated with worse global longitudinal strainRisk stratification strategiesHigh-risk groupMonths post-treatmentPost hoc analysisElectrocardiographic (ECGTrastuzumab exposureLymphoma therapySystolic dysfunctionAI-ECGBefore treatmentRisk biomarkersLongitudinal strainLow riskStratification strategiesHigher incidencePositive screen
2023
Detection of Left Ventricular Systolic Dysfunction From Electrocardiographic Images
Sangha V, Nargesi A, Dhingra L, Khunte A, Mortazavi B, Ribeiro A, Banina E, Adeola O, Garg N, Brandt C, Miller E, Ribeiro A, Velazquez E, Giatti L, Barreto S, Foppa M, Yuan N, Ouyang D, Krumholz H, Khera R. Detection of Left Ventricular Systolic Dysfunction From Electrocardiographic Images. Circulation 2023, 148: 765-777. PMID: 37489538, PMCID: PMC10982757, DOI: 10.1161/circulationaha.122.062646.Peer-Reviewed Original ResearchConceptsLV systolic dysfunctionYale-New Haven HospitalVentricular systolic dysfunctionSystolic dysfunctionLV ejection fractionBrazilian Longitudinal StudyNew Haven HospitalEjection fractionCardiology clinicRegional hospitalLeft ventricular systolic dysfunctionCedars-Sinai Medical CenterAdult Health (ELSA-Brasil) cohort
2015
National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient‐centered Evaluation Assessment of Cardiac Events (PEACE)‐Retrospective AMI Study, 2001, 2006, and 2011
Guan W, Murugiah K, Downing N, Li J, Wang Q, Ross JS, Desai NR, Masoudi FA, Spertus JA, Li X, Krumholz HM, Jiang L, Group T. National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient‐centered Evaluation Assessment of Cardiac Events (PEACE)‐Retrospective AMI Study, 2001, 2006, and 2011. Journal Of The American Heart Association 2015, 4: e001718. PMID: 26071031, PMCID: PMC4599529, DOI: 10.1161/jaha.114.001718.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionHeart failureMyocardial infarctionUse of spironolactoneNational practice patternsProportion of patientsAssessment of eligibilitySpironolactone useAldosterone antagonistsSystolic dysfunctionCardiac eventsAMI patientsChina PatientPatient eligibilityPatient groupUnknown indicationPractice patternsIdeal patientPatientsSpironolactoneEligibilityAppropriate useInfarctionDiabetesNational quality assessment
2008
Prevention of Heart Failure
Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB, Hong Y. Prevention of Heart Failure. Circulation 2008, 117: 2544-2565. PMID: 18391114, DOI: 10.1161/circulationaha.107.188965.Peer-Reviewed Original ResearchConceptsPrevention of HFChronic kidney diseaseCoronary heart diseaseKidney diseaseHeart diseaseRisk factorsAsymptomatic left ventricular systolic dysfunctionLeft ventricular systolic dysfunctionLeft ventricular systolic functionHF prevention strategiesVentricular systolic dysfunctionVentricular systolic functionHeart failure ratesDevelopment of HFNational awareness campaignGenetic risk factorsEvidence-based managementSystolic dysfunctionSystolic functionHeart failurePatient groupPathophysiological basisPrevention strategiesDiseaseEarly detection
2006
Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction
Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD, Investigators F. Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction. Journal Of The American Society Of Nephrology 2006, 17: 2886-2891. PMID: 16928807, DOI: 10.1681/asn.2006010063.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionCaptopril groupCardiovascular riskRenal functionSerum creatininePotent independent risk factorVentricular Enlargement (SAVE) trialBaseline renal functionHeart failure populationComposite end pointIndependent risk factorSerum creatinine measurementsBaseline creatinineCardiovascular deathCardiovascular morbidityPlacebo groupRenal dysfunctionSystolic dysfunctionVentricular dysfunctionAdverse eventsPrognostic importanceFailure populationTherapeutic choiceRisk factors
2005
Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001
Masoudi FA, Gross CP, Wang Y, Rathore SS, Havranek EP, Foody JM, Krumholz HM. Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001. Circulation 2005, 112: 39-47. PMID: 15983243, DOI: 10.1161/circulationaha.104.527549.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCohort StudiesCreatinineDiureticsDrug PrescriptionsFemaleFollow-Up StudiesHeart FailureHumansMaleMineralocorticoid Receptor AntagonistsPatient SelectionPotassiumRandomized Controlled Trials as TopicRisk AssessmentSpironolactoneUnited StatesVentricular Dysfunction, LeftConceptsRandomized Aldactone Evaluation StudyPublication of RALESVentricular systolic dysfunctionHeart failureEnrollment criteriaSpironolactone prescriptionSpironolactone therapySystolic dysfunctionOlder patientsLeft ventricular systolic dysfunctionPatients meeting enrollment criteriaSerial cross-sectional samplesSevere renal dysfunctionSerum creatinine valuesAldactone Evaluation StudyMultivariable logistic regressionSerum potassium valuesSkilled nursing facilitiesNoncardiovascular comorbiditiesSpironolactone useRenal dysfunctionAdverse eventsHospital dischargeAppropriate patientsMultivariable analysis
2004
National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM. National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation 2004, 110: 724-731. PMID: 15289383, DOI: 10.1161/01.cir.0000138934.28340.ed.Peer-Reviewed Original ResearchConceptsACE inhibitor prescriptionAngiotensin receptor blockersVentricular systolic dysfunctionHeart failureACE inhibitorsInhibitor prescriptionSystolic dysfunctionOlder patientsLeft ventricular systolic dysfunctionAngiotensin converting enzyme (ACE) inhibitorsSerum creatinine levelsACE inhibitor useCreatinine levelsHospital factorsInhibitor useReceptor blockersSerum creatininePatient genderClinical trialsTherapeutic substitutionLower riskEnzyme inhibitorsLower mortalityPatientsSecondary analysisAdverse Effects of β-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials
Ko DT, Hebert PR, Coffey CS, Curtis JP, Foody JM, Sedrakyan A, Krumholz HM. Adverse Effects of β-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials. JAMA Internal Medicine 2004, 164: 1389-1394. PMID: 15249347, DOI: 10.1001/archinte.164.13.1389.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedBisoprololBradycardiaCarbazolesCarvedilolDizzinessFatigueFemaleFollow-Up StudiesHeart Conduction SystemHeart FailureHumansHypotensionMaleMetoprololMiddle AgedPropanolaminesRisk FactorsRisk Reduction BehaviorSeverity of Illness IndexStatistics as TopicTreatment FailureVentricular Dysfunction, LeftWithholding TreatmentConceptsBeta-blocker therapyHeart failureAdverse effectsLeft ventricular systolic dysfunctionBeta-blocker trialsCardiovascular adverse effectsChronic heart failureHeart Failure TrialVentricular systolic dysfunctionΒ-blocker therapyRisk of hypotensionLife-saving therapyRandom-effects modelHF hospitalizationCause mortalitySystolic dysfunctionCause withdrawalsFailure TrialRandomized trialsAbsolute riskElectronic searchPatientsMEDLINE databaseTherapyAbsolute increase838-1 National patterns of spironolactone prescription for older patients with heart failure and left ventricular systolic dysfunction before and after RALES
Masoudi F, Gross C, Wang Y, Havranek E, Rathore S, Foody J, Krumholz H. 838-1 National patterns of spironolactone prescription for older patients with heart failure and left ventricular systolic dysfunction before and after RALES. Journal Of The American College Of Cardiology 2004, 43: a415. DOI: 10.1016/s0735-1097(04)91750-0.Peer-Reviewed Original Research
2003
The effectiveness of angiotensin converting enzyme inhibitors in medicare beneficiaries with heart failure and left ventricular systolic dysfunction: results of the National Heart Care Project
Masoudi F, Rathore S, Wang Y, Havranek E, Foody J, Krumholz H. The effectiveness of angiotensin converting enzyme inhibitors in medicare beneficiaries with heart failure and left ventricular systolic dysfunction: results of the National Heart Care Project. Journal Of Cardiac Failure 2003, 9: s86. DOI: 10.1016/s1071-9164(03)00163-5.Peer-Reviewed Original ResearchNational and State Trends in Quality of Care for Acute Myocardial Infarction Between 1994-1995 and 1998-1999: The Medicare Health Care Quality Improvement Program
Burwen DR, Galusha DH, Lewis JM, Bedinger MR, Radford MJ, Krumholz HM, Foody JM. National and State Trends in Quality of Care for Acute Myocardial Infarction Between 1994-1995 and 1998-1999: The Medicare Health Care Quality Improvement Program. JAMA Internal Medicine 2003, 163: 1430-1439. PMID: 12824092, DOI: 10.1001/archinte.163.12.1430.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAngiotensin-Converting Enzyme InhibitorsAspirinFemaleHealth Care SurveysHumansMaleMedicareMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsQuality Indicators, Health CareQuality of Health CareSmoking CessationThrombolytic TherapyTime FactorsUnited StatesConceptsAcute myocardial infarctionQuality of careHospital arrivalEarly administrationMedian timeMyocardial infarctionPrimary percutaneous transluminal coronary angioplastyHealth Care Quality Improvement ProgramPercutaneous transluminal coronary angioplastyAcute reperfusion therapyBeta-blocker prescriptionEnzyme inhibitor prescriptionTransluminal coronary angioplastyGuideline-recommended processesQuality Improvement ProgramPopulation-based improvementsCessation counselingReperfusion therapySystolic dysfunctionInhibitor prescriptionCoronary angioplastyThrombolytic therapyMedicare patientsTherapyTime points
2002
β-Blockers in Heart Failure: Clinical Applications
Farrell MH, Foody JM, Krumholz HM. β-Blockers in Heart Failure: Clinical Applications. JAMA 2002, 287: 890-897. PMID: 11851583, DOI: 10.1001/jama.287.7.890.Peer-Reviewed Original ResearchConceptsHeart failureLeft ventricular systolic dysfunctionVentricular systolic dysfunctionHeart failure patientsQuality of careSeries of casesSystolic dysfunctionFailure patientsPatient selectionConsensus guidelinesFluid statusΒ-blockersPatientsScientific evidenceClinical applicationCareGuidelinesSafetyMorbidityFailureDysfunctionTherapyMortalityβ-Blocker Therapy in Heart Failure: Scientific Review
Foody JM, Farrell MH, Krumholz HM. β-Blocker Therapy in Heart Failure: Scientific Review. JAMA 2002, 287: 883-889. PMID: 11851582, DOI: 10.1001/jama.287.7.883.Peer-Reviewed Original ResearchConceptsHeart failure patientsHeart failureClinical trialsFailure patientsClinical outcomesClass IIDrug Administration indicationsBeta-blocker usePrimary end pointΒ-blocker therapyScientific rationaleTreatment of patientsCare of patientsEnglish-language articlesPotential physiologic roleBasic science studiesClass of agentsSystolic dysfunctionMortality benefitPlacebo treatmentDATA EXTRACTIONClinical guidelinesSTUDY SELECTIONCurrent recommendationsPatientsMortality associated with the quality of care of patients hospitalized with congestive heart failure
Luthi J, Mcclellan WM, Fitzgerald D, Krumholz HM, Delaney RJ, Bratzler DW, Elward K, Cangialose C, Ballard D. Mortality associated with the quality of care of patients hospitalized with congestive heart failure. International Journal For Quality In Health Care 2002, 14: 15-24. PMID: 11871625, DOI: 10.1093/intqhc/14.1.15.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsCohort StudiesGuideline AdherenceHeart FailureHospital MortalityHospitalizationHumansMedicareOutcome and Process Assessment, Health CarePatient DischargeProportional Hazards ModelsQuality of Health CareRetrospective StudiesRisk AssessmentSurvival AnalysisUnited StatesVentricular Dysfunction, LeftConceptsLeft ventricular systolic dysfunctionCongestive heart failureRisk of deathElderly patientsHazard ratioHeart failurePresence of LVSDAdjusted hazard ratioRetrospective cohort studyUse of angiotensinVentricular systolic dysfunctionClinical practice guidelinesQuality of careACEI doseACEI treatmentSystolic dysfunctionCohort studyDischarge medicationsEjection fractionVentricular functionMean agePractice guidelinesACEIMedicare beneficiariesPatients
2001
Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure
Chen Y, Wang Y, Radford M, Krumholz H. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. American Heart Journal 2001, 141: 410-417. PMID: 11231438, DOI: 10.1067/mhj.2001.113227.Peer-Reviewed Original ResearchConceptsACE inhibitorsHeart failureClinical trialsSystolic dysfunctionElderly patientsLow dosesConfirmed heart failureDosage of angiotensinRepresentative elderly cohortDose-response relationshipHospital dischargeClinical factorsGuideline recommendationsElderly cohortMedication dataMedical recordsAdministrative databasesConnecticut hospitalsPractice guidelinesEnzyme inhibitorsPatientsLower mortalityHigh dosesDosesMortality
2000
Variations among hospitals in the quality of care for heart failure.
Luthi JC, McClellan WM, Fitzgerald D, Herrin J, Delaney RJ, Krumholz HM, Bratzler DW, Elward K, Cangialose CB, Ballard DJ. Variations among hospitals in the quality of care for heart failure. Effective Clinical Practice : ECP 2000, 3: 69-77. PMID: 10915326.Peer-Reviewed Original ResearchConceptsQuality of careCongestive heart failureLeft ventricular functionHeart failureVentricular functionEnzyme inhibitorsLeft ventricular systolic dysfunctionAngiotensin-converting enzyme inhibitorDaily weight monitoringPercent of patientsVentricular systolic dysfunctionProportion of patientsHospital medical recordsLow sodium dietQuality Improvement ProgramSubstantial hospitalSystolic dysfunctionDischarge medicationsHospital variationDischarge instructionsMedical recordsPractice patternsPatientsTarget doseWeight monitoring
1999
Variations in and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction.
Krumholz HM, Chen YT, Bradford WD, Cerese J. Variations in and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction. The American Journal Of Managed Care 1999, 5: 715-23. PMID: 10538451.Peer-Reviewed Original ResearchConceptsLength of stayCongestive heart failureHeart failureSystolic dysfunctionPatient characteristicsAcademic hospitalCollaborative quality improvement projectIndividual hospitalsAdmission clinical characteristicsRetrospective cohort studyPrincipal discharge diagnosisNumber of patientsQuality improvement projectUniversity HealthSystem ConsortiumCorrelates of lengthHospital stayPeripheral edemaClinical characteristicsCohort studyRenal failureClinical factorsMajor complicationsHospital eventsRegression modelsAtrial fibrillation